Ventricular fibrillation during coronary angiography: reduced incidence in man with contrast media lacking calcium binding additives.
The intracoronary injection of contrast media during coronary angiography occasionally results in ventricular fibrillation. Experimental studies have implicated the calcium sequestering agents, sodium citrate and EDTA in Renografin 76 (RG76), as contributing to this complication. Angiovist 370 (AV370) is a contrast medium similar to RG76 except that it contains disodium calcium EDTA instead of EDTA and sodium citrate. To determine if contrast media lacking sodium citrate and EDTA will result in a lower incidence of ventricular fibrillation in man, this investigation compared the incidence of contrast media-induced ventricular fibrillation in patients undergoing coronary angiography with RG76 to that with AV370. Group A consisted of 2,500 consecutive patients undergoing coronary angiography with RG76 and group B consisted of 2,000 subsequent consecutive patients in whom AV370 was employed as the contrast medium. There was no significant difference between groups A and B with respect to the volume of contrast media used per patient (153 +/- 49 ml vs 154 +/- 45ml), age (58.4 +/- 10 vs 58.6 +/- 10 years), sex (70% male vs 70% male), ejection fraction (59 +/- 17 vs 60 +/- 20), history of mitral valve disease (5.8% vs 7.1%), history of aortic valve disease (6.7% vs 6.5%), prior coronary artery bypass graft surgery (6.6% vs 7.3%), or extent of coronary artery disease. Fifteen episodes of contrast media-induced ventricular fibrillation occurred in group A (incidence 0.6%) whereas two episodes occurred in group B (incidence 0.1%) (p less than 0.02). Each patient was successfully defibrillated and no adverse sequelae resulted. Thus the present investigation suggests that the incidence of ventricular fibrillation during coronary angiography can be significantly decreased by using contrast media lacking sodium citrate and EDTA.
D000368:Aged; D000792:Angiography / Q000009:adverse effects*; D006328:Cardiac Catheterization; D002951:Citrates / Q000009:adverse effects; D019343:Citric Acid; D003287:Contrast Media / Q000009:adverse effects*; D017023:Coronary Angiography; D003973:Diatrizoate / Q000009:adverse effects* / Q000031:analogs & derivatives*; D003974:Diatrizoate Meglumine / Q000009:adverse effects*; D004338:Drug Combinations / Q000009:adverse effects; D004492:Edetic Acid / Q000009:adverse effects; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D014693:Ventricular Fibrillation / Q000139:chemically induced*
D002951:Citrates; D003287:Contrast Media; D004338:Drug Combinations; D003973:Diatrizoate; D019343:Citric Acid; D003974:Diatrizoate Meglumine; C027278:urovision; D004492:Edetic Acid